Acción PHIO PHIO PHARMACEUTICALS CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Phio Pharmaceuticals Corp.

Acciones

PHIO

US71880W4024

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 19:42:41 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,797 USD +2,75 % Gráfico intradía de Phio Pharmaceuticals Corp. +17,89 % +5,79 %
22/04 Phio Pharmaceuticals Corp. Presenta nuevos datos sobre su principal candidato a producto clínico, el PH-762 CI
16/04 Phio Pharmaceuticals anuncia sus próximas presentaciones en la 81ª Reunión Anual de la Sociedad de Dermatología de Investigación (SID) CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
National Spotlight Features Phio’s Innovative RNAi Technology Platform
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
North American Morning Briefing : Stocks Seen -2-
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción PHIO
  4. Noticias Phio Pharmaceuticals Corp.
  5. Otros idiomas